Insception Biosciences Begins Human Clinical Trials of Stem Cell Treatment That Could Replace Bone Marrow Transplants

07-Feb-2008

Insception Biosciences Inc., a privately-held company that develops stem cell treatments, announced it has received approval from the food and Drug Administration (FDA) to begin human clinical studies of a new stem cell treatment, which offers an alternative to bone marrow transplants.

Cord blood, which offers a rich source of blood stem cells, is now clinically accepted as a viable alternative to bone marrow or peripheral blood as sources of stem cells for transplantation and treatment of a variety of blood, cancer and genetic disorders. To date, one of the barriers to the widespread use of cord blood has been the low number of stem cells in cord blood samples. This has, by and large, limited its use to pediatric patients. However, Insception Biosciences' new cellular product, called INSC01, contains an enriched number of stem cells from umbilical cord blood which will broaden the use of cord blood stem cells for adult transplants.

"This is a major milestone, not only for Insception but also for the advancement of cord blood stem cell treatments," says Dr. Laura Grey, VP Research and Business Development at Insception Biosciences. "Cord blood is not only an alternative stem cell source to bone marrow, it provides the significant advantages of being easily collected and can be stored as a frozen product, which means it is readily available with minimal waiting times. Ultimately, this technology could be applied in the future to help patients who cannot find a suitable donor or who cannot afford to wait for a bone marrow transplant."

https://www.bionity.com/en/news/77594/insception-biosciences-begins-human-clinical-trials-of-stem-cell-treatment-that-could-replace-bone-marrow-transplants.html